Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Dose Ranging, Multi-Centre, Prospective First in Human Study to Assess the Safety of the ADAM System

NCT05134428 is registered in ClinicalTrials.gov with Contraline, Inc as lead sponsor.

NCT NCT05134428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05134428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Dose Ranging, Multi-Centre, Prospective First in Human Study to Assess the Safety of the ADAM System
Lead sponsor
Contraline, Inc
Phase
Not applicable
Overall status
Completed
Start date
May 20, 2022
Completion date
March 8, 2026
Enrollment
25 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy male adults, male contraception